Cargando…

SC06, a novel small molecule compound, displays preclinical activity against multiple myeloma by disrupting the mTOR signaling pathway

The mammalian target of rapamycin (mTOR) is extensively involved in multiple myeloma (MM) pathophysiology. In the present study, we reported a novel small molecule SC06 that induced MM cell apoptosis and delayed MM xenograft growth in vivo. Oral administration of SC06 to mice bearing human MM xenogr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Kunkun, Xu, Xin, Xu, Zhuan, Chen, Guodong, Zeng, Yuanying, Zhang, Zubin, Cao, Biyin, Kong, Yan, Tang, Xiaowen, Mao, Xinliang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4556980/ https://www.ncbi.nlm.nih.gov/pubmed/26329846 http://dx.doi.org/10.1038/srep12809

Ejemplares similares

Clioquinol induces pro-death autophagy in leukemia and myeloma cells by disrupting the mTOR signaling pathway
por: Cao, Biyin, et al.
Publicado: (2014)

An inhibitor of cholesterol absorption displays anti-myeloma activity by targeting the JAK2-STAT3 signaling pathway
por: Xu, Xin, et al.
Publicado: (2016)

A novel PI3K inhibitor PIK-C98 displays potent preclinical activity against multiple myeloma
por: Zhu, Jingyu, et al.
Publicado: (2014)

Correction: A novel PI3K inhibitor PIK-C98 displays potent preclinical activity against multiple myeloma
por: Zhu, Jingyu, et al.
Publicado: (2019)

Identification of a promising PI3K inhibitor for the treatment of multiple myeloma through the structural optimization
por: Han, Kunkun, et al.
Publicado: (2014)

Anti-bacterial and anti-viral nanchangmycin displays anti-myeloma activity by targeting Otub1 and c-Maf
por: Xu, Yujia, et al.
Publicado: (2020)

A novel small molecule agent displays potent anti-myeloma activity by inhibiting the JAK2-STAT3 signaling pathway
por: Zhang, Zubin, et al.
Publicado: (2016)

Correction: A novel small molecule agent displays potent anti-myeloma activity by inhibiting the JAK2-STAT3 signaling pathway
por: Zhang, Zubin, et al.
Publicado: (2016)

Ring finger protein 6 promotes breast cancer cell proliferation by stabilizing estrogen receptor alpha
por: Zeng, Yuanying, et al.
Publicado: (2017)

Inhibition of the Otub1/c-Maf axis by the herbal acevaltrate induces myeloma cell apoptosis
por: Sun, Tong, et al.
Publicado: (2021)

Saponins From Paris forrestii (Takht.) H. Li Display Potent Activity Against Acute Myeloid Leukemia by Suppressing the RNF6/AKT/mTOR Signaling Pathway
por: Lu, Qin, et al.
Publicado: (2018)

The ubiquitin-conjugating enzyme UBE2O modulates c-Maf stability and induces myeloma cell apoptosis
por: Xu, Yujia, et al.
Publicado: (2017)

Inhibition of the deubiquitinase USP5 leads to c-Maf protein degradation and myeloma cell apoptosis
por: Wang, Siyu, et al.
Publicado: (2017)

A virtual screen identified C96 as a novel inhibitor of phosphatidylinositol 3-kinase that displays potent preclinical activity against multiple myeloma in vitro and in vivo
por: Tang, Juan, et al.
Publicado: (2014)

The deubiquitinase USP10 restores PTEN activity and inhibits non–small cell lung cancer cell proliferation
por: He, Yuanming, et al.
Publicado: (2021)

Induction of zinc finger protein RNF6 auto-ubiquitination for the treatment of myeloma and chronic myeloid leukemia
por: Zhuang, Haixia, et al.
Publicado: (2022)

Anesthetics disrupt brain development via actions on the mTOR pathway
por: Xu, Jing, et al.
Publicado: (2018)

Targeting mTOR in Glioblastoma: Rationale and Preclinical/Clinical Evidence
por: Mecca, Carmen, et al.
Publicado: (2018)

The ubiquitin ligase HERC4 suppresses MafA transcriptional activity triggered by GSK3β in myeloma by atypical K63-linked polyubiquitination
por: Zhang, Zubin, et al.
Publicado: (2023)

Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer
por: Garrido-Laguna, I, et al.
Publicado: (2010)

Interferon-stimulated gene 15 induces cancer cell death by suppressing the NF-κB signaling pathway
por: Mao, Hongwu, et al.
Publicado: (2016)

Disruption of mTOR and MAPK pathways correlates with severity in idiopathic autism
por: Rosina, Eleonora, et al.
Publicado: (2019)

Inhibition of mTOR complex 2 restrains tumor angiogenesis in multiple myeloma
por: Lamanuzzi, Aurelia, et al.
Publicado: (2018)

PLPPR4 haploinsufficiency causes neurodevelopmental disorders by disrupting synaptic plasticity via mTOR signalling
por: Li, Huanzheng, et al.
Publicado: (2023)

Glycolysis is suppressed by DCZ0801-induced inactivation of the Akt/mTOR pathway in Multiple Myeloma
por: Feng, Qilin, et al.
Publicado: (2020)

mTOR pathway activation in multiple myeloma cell lines and primary tumour cells: pomalidomide enhances cytoplasmic-nuclear shuttling of mTOR protein
por: Guglielmelli, Tommasina, et al.
Publicado: (2015)

mTOR Signaling Disruption and Its Association with the Development of Autism Spectrum Disorder
por: Thomas, Shilu Deepa, et al.
Publicado: (2023)

EPHA3 enhances macrophage autophagy and apoptosis by disrupting the mTOR signaling pathway in mice with endometriosis
por: Xu, Hongmei, et al.
Publicado: (2019)

MK2206 enhances the cytocidal effects of bufalin in multiple myeloma by inhibiting the AKT/mTOR pathway
por: Xiang, Ru-Fang, et al.
Publicado: (2017)

Probiotic Bacillus amyloliquefaciens SC06 Induces Autophagy to Protect against Pathogens in Macrophages
por: Wu, Yanping, et al.
Publicado: (2017)

Adiponectin inhibits the differentiation and maturation of osteoclasts via the mTOR pathway in multiple myeloma
por: Liu, Zhaoyun, et al.
Publicado: (2020)

mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
por: Gao, Wei, et al.
Publicado: (2012)

Myelination and mTOR
por: Figlia, Gianluca, et al.
Publicado: (2017)

Combination Treatment Targeting mTOR and MAPK Pathways Has Synergistic Activity in Multiple Myeloma
por: Sun, Kaiyan, et al.
Publicado: (2023)

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
por: Zou, Zhilin, et al.
Publicado: (2020)

Gold Nanoparticles Disrupt the IGFBP2/mTOR/PTEN Axis to Inhibit Ovarian Cancer Growth
por: Hossen, Md. Nazir, et al.
Publicado: (2022)

Preclinical evaluation of the PI3K/Akt/mTOR pathway in animal models of multiple sclerosis
por: Mammana, Santa, et al.
Publicado: (2018)

Preclinical Efficacy and Involvement of AKT, mTOR, and ERK Kinases in the Mechanism of Sulforaphane against Endometrial Cancer
por: Rai, Rajani, et al.
Publicado: (2020)

mTOR inhibition by TAK‐228 is effective against growth, survival and angiogenesis in preclinical retinoblastoma models
por: Tang, Lanlan, et al.
Publicado: (2022)

mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
por: Tian, Tian, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_b3ap98tojven3vb3cf9vbkj92j